Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 651-662

  Safari, Dodi ^a   Marradi, Marco ^b,c   Chiodo, Fabrizio ^c   Th Dekker, Huberta A ^a   Shan, Yulong ^d   Adamo, Roberto ^e   Oscarson, Stefan ^f   Rijkers, Ger T ^g   Lahmann, Martina ^d   Kamerling, Johannis P ^e   Penadés, Soledad ^b,c   Snippe, Harm ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CIC BIOMAGUNE   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d BANGOR UNIVERSITY   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

^g ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

antibody; gold nanoparticle; mice immunization; OVA323 339 peptide; Streptococcus pneumoniae; synthetic carbohydrate vaccine

Indexed keywords

EPITOPE; GLUCOSE; GOLD GLYCONANOPARTICLE; GOLD NANOPARTICLE; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS PNEUMONIAE TYPE 14 CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKOCYTE; MOUSE; NONHUMAN; ONE POT SYNTHESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; BACTERIAL CAPSULES; BACTERIAL VACCINES; CARBOHYDRATES; DRUG DELIVERY SYSTEMS; EPITOPES; GOLD; HUMANS; MICE; NANOPARTICLES; PHAGOCYTOSIS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84861631736     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.151     Document Type: Article

References (50)

1. Pena Icart L, Fernández-Santana V, Veloso RC et al. Protective immunity of pneumococcal glycoconjugates. In: Carbohydrate-Based Vaccines (Volume 989). René Roy (Ed.). ACS Symposium Series, American Chemical Society, Washington, DC, USA, 1-19 (2008).
2. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9, 308-324 (2010).
3. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003). (Pubitemid 36514704)
4. Verez-Bencomo V, Fernández-Santana V, Hardy E et al. A synthetic conjugate polysaccharide vaccine against Haemophilus infuenzae type b. Science 305, 522-525 (2004). (Pubitemid 38971343)
5. Schutze MP, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135, 2319-2322 (1985). (Pubitemid 16217114)
6. Stallforth P, Lepenies B, Adibekian A, Seeberger PH. Carbohydrates: a frontier in medicinal chemistry. J. Med. Chem. 52, 5561-5577 (2009).
7. Keding SJ, Danishefsky S. Synthetic Carbohydrate-Based Vaccines. In: Carbohydrate-Based Drug Discovery. Chi-Huey Wong (Ed.), Wiley-VCH Verlag, Berlin, Germany, 381-406 (2003).
8. Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat. Chem. Biol. 3, 663-667 (2007). (Pubitemid 47417705)
9. Hassane FS, Phalipon A, Tanguy M et al. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella fexneri 2a O-antigen. Vaccine 27, 5419-5426 (2009).
10. Wang SK, Liang PH, Astronomo RD, Hsu TL et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl Acad. Sci. USA 105, 3690-3695 (2008). (Pubitemid 351723459)
11. Joyce JG, Krauss IJ, Song HC et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specifc antibodies that fail to neutralize HIV-1 virions. Proc. Natl Acad. Sci. USA 105, 15684-15689. (2008).
12. Song EH, Osanya AO, Petersen CA, Pohl NL. Synthesis of multivalent tuberculosis and Leishmania-associated capping carbohydrates reveals structure-dependent responses allowing immune evasion. J. Am. Chem. Soc. 132, 11428-11430 (2010).
13. Sarkar S, Lombardo SA, Herner DN, Talan RS, Wall KA, Sucheck SJ. Synthesis of single-molecules L-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. J. Am. Chem. Soc. 132, 17236-17246 (2010).
14. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 3, 343-355 (2008). (Pubitemid 351827311)
15. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28, 215-236 (2011).
16. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity Chem. Soc. Rev. 38, 1759-1782 (2009).
17. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl Acad. Sci. USA 87, 9568-9572 (1990). (Pubitemid 120016484)
18. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-778 (2001).
19. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for infuenza is immunogenic in humans. Vaccine 24, 4475-4481 (2006). (Pubitemid 43776768)
20. Castillo PM, Herrera JL, Fernandez-Montesinos R et al. Tiopronin monolayer-protected silver nanoparticles modulate IL-6 secretion mediated by Toll-like receptor ligands. Nanomedicine 3, 627-635 (2008).
21. Bastús NG, Sánchez-Tilló E, Pujals S et al. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol. 46, 743-748 (2009).
22. Snippe H, Jansen WTM, Kamerling JP. Immunology of Experimental Synthetic Carbohydrate-Protein Conjugate Vaccines Against Streptococcus pneumoniae Serotypes. In: Carbohydrate-Based Vaccines (Volume 989). René Roy (Ed.). ACS Symposium Series, American Chemical Society, Washington, DC, USA, 85-104 (2008).
23. Rijkers GT, van Mens SP, van Velzen-Blad H. What do the next 100 years hold for pneumococcal vaccination? Expert Rev. Vaccines 9, 1241-1244 (2010).
24. Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361, 2189-2195 (2003). (Pubitemid 36782552)
25. 197. Infect. Immun. 70, 5107-5114 (2002).
26. Safari D, Dekker HAT, Joosten JAF et al. Identifcation of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infect. Immun. 76, 4615-4623 (2008).
27. Barrientos AG, de la Fuente JM, Rojas TC, Fernandez A, Penadés S. Gold glyconanoparticles: synthetic polyvalent ligands mimicking glycocalyx-like surfaces as tools for glycobiological studies. Chem. Eur. J. 9, 1909-1921 (2003).
28. Martínez-Ávila O, Hijazi K, Marradi M et al. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem. Eur. J. 15, 9874-9888 (2009).
29. Ojeda R, de Paz JL, Barrientos AG, Martín-Lomas M, Penadés S. Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines. Carbohydr. Res. 342, 448-459 (2007). (Pubitemid 46161419)
30. Marradi M, Martín-Lomas M, Penadés S. Glyconanoparticles: polyvalent tools to study carbohydrate-based interactions. Adv. Carbohydr. Chem. Biochem. 64, 211-290 (2010).
31. García I, Marradi M, Penadés S. Glyconanoparticles: multifunctional nanomaterials for biomedical applications. Nanomedicine 5, 777-792 (2010).
32. Buus S, Colon S, Smith C, Freed JH, Miles C, Grey HM. Interaction between a 'processed' ovalbumin peptide and Ia molecules. Proc. Natl Acad. Sci. USA 83, 3968-3971 (1986). (Pubitemid 16062403)
33. Renz H, Bradley K, Larsen GL, McCall C, Gelfand EW. Comparison of the allergenicity of ovalbumin and ovalbumin peptide 323-339. Differential expansion of V beta-expressing T cell populations. J. Immunol. 151, 7206-7213 (1993). (Pubitemid 24001095)
34. Sundgren A, Lahmann M, Oscarson S. Block synthesis of Streptococcus pneumoniae type 14 capsular polysaccharide structures. J. Carbohydr. Chem. 24, 379-391 (2005). (Pubitemid 41653657)
35. Hostetler MJ, Wingate JE, Zhong C-J et al. Alkanethiolate gold cluster molecules with core diameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size. Langmuir 14, 17-30 (1998). (Pubitemid 128575442)
36. Jansen WTM, Gootjes J, Zelle M et al. Use of highly encapsulated Streptococcus pneumoniae strains in a fow-cytometric assay for assessment of the phagocytic capacity of serotype-specifc antibodies. Clin. Diagn. Lab. Immunol. 5, 703-710 (1998). (Pubitemid 29030768)
37. Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem. Rev. 105, 1103-1169 (2005). (Pubitemid 40600878)
38. Svetic A, Finkelman FD, Jian YC et al. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147, 2391-2397 (1991).
39. + T cells. Int. Immunol. 5, 877-883 (1993). (Pubitemid 23241759)
40. Mrksich M, Whitesides GM. Using self-assembled monolayers to understand the interactions of man-made surfaces with proteins and cells. Annu. Rev. Biophys. Biomol. Struct. 25, 55-78 (1996).
41. Safari D, Dekker HAT, Rijkers G, Snippe H. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates. Vaccine 29, 849-854 (2011).
42. Smith KA. Interleukin-2: inception, impact, and implications. Science 240, 1169-1176 (1988).
43. Randall TD, Lund FE, Brewer JW, Aldridge C, Wall R, Corley RB. Interleukin-5 (IL-5) and IL-6 defne two molecularly distinct pathways of B-cell differentiation. Mol. Cell. Biol. 13, 3929-3936 (1993). (Pubitemid 23187621)
44. Wuorimaa T, Käyhty H, Eskola J, Bloigu A, Leroy O, Surcel HM. Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccine. Scand. J. Immunol. 53, 422-428 (2001). (Pubitemid 32275701)
45. Cox CA, Shi G, Yin H et al. Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J. Immunol. 180, 7417-7422 (2008).
46. Lu Y, Gross J, Bogaert D et al. Interleukin IL-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4, e1000159 (2008).
47. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J. Clin. Invest. 119, 1899-1909 (2009).
48. Baker WS. Carcinoma of the uterine cervix: Interstitial radioactive colloidal gold therapy of the lateral pelvic nodes. Calif. Med. 92, 25-30 (1960).
49. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine 2, 789-803 (2007).
50. Kennedy LC, Bickford LR, Lewinski NA et al. New era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 7, 169-183 (2011).